Showing 2,321 - 2,340 results of 3,614 for search '(( significant decrease decrease ) OR ( significant risk decrease ))~', query time: 0.33s Refine Results
  1. 2321

    <b>Prevalence and Correlates of Diabetes Distress in Pregnant Individuals With Preexisting Diabetes: A Cross-Sectional Study</b> by Holly Tschirhart (823039)

    Published 2024
    “…Age ≥35 years of age and higher education levels were significantly associated with scores on the Problem Areas in Diabetes (PAID) scale, which measures diabetes-related emotional distress (decreases of 10.18 and 11.77 points, respectively, P = 0.04). …”
  2. 2322

    Table 1_Does screening mode matter? A repeated cross-sectional study of computer self-administered vs. clinician-administered screening of youth substance use in pediatric primary... by Chloe Gao (11107228)

    Published 2025
    “…Introduction<p>Universal youth substance use screening in pediatric primary care enables early detection and intervention, which, in turn, can help decrease the risk of problematic substance use. Screening mode [electronic self-administered survey (SA) vs. clinician-administered interview (CA)] may influence whether substance use is reported and, therefore, clinical decisions about whether and how to intervene.…”
  3. 2323

    Impact of Oral Semaglutide on Kidney Outcomes in People with Type 2 Diabetes: Results from the SOUL Randomized Trial by Johannes F. E. Mann (22017555)

    Published 2025
    “…</p><p dir="ltr">RESEARCH DESIGN AND METHODS</p><p dir="ltr">SOUL (NCT03914326), a randomized, double-blind trial, compared oral semaglutide vs placebo in people with T2D, ASCVD, and/or CKD, showing a 14% reduction in risk of major adverse CV events. Prespecified kidney outcomes included a 5-point composite (≥50% decrease in estimated glomerular filtration rate [eGFR], persistent eGFR <15 mL/min/1.73 m2, initiation of chronic kidney replacement therapy, or death from kidney or CV causes); a 4-point composite (excluding CV death); and eGFR decline. …”
  4. 2324

    Video 1_Characterizing the structural properties and porosity of mid-urethral slings with varied manufacturing techniques.mov by Katrina Knight (17391604)

    Published 2025
    “…</p>Discussion<p>Overall, heat-sealing decreased deformability at the cost of markedly increasing device stiffness to a point which likely outweighs benefits, and risks increased complications. …”
  5. 2325

    Video 2_Characterizing the structural properties and porosity of mid-urethral slings with varied manufacturing techniques.mov by Katrina Knight (17391604)

    Published 2025
    “…</p>Discussion<p>Overall, heat-sealing decreased deformability at the cost of markedly increasing device stiffness to a point which likely outweighs benefits, and risks increased complications. …”
  6. 2326

    Video 3_Characterizing the structural properties and porosity of mid-urethral slings with varied manufacturing techniques.mov by Katrina Knight (17391604)

    Published 2025
    “…</p>Discussion<p>Overall, heat-sealing decreased deformability at the cost of markedly increasing device stiffness to a point which likely outweighs benefits, and risks increased complications. …”
  7. 2327

    Video 5_Characterizing the structural properties and porosity of mid-urethral slings with varied manufacturing techniques.mov by Katrina Knight (17391604)

    Published 2025
    “…</p>Discussion<p>Overall, heat-sealing decreased deformability at the cost of markedly increasing device stiffness to a point which likely outweighs benefits, and risks increased complications. …”
  8. 2328

    Video 4_Characterizing the structural properties and porosity of mid-urethral slings with varied manufacturing techniques.mov by Katrina Knight (17391604)

    Published 2025
    “…</p>Discussion<p>Overall, heat-sealing decreased deformability at the cost of markedly increasing device stiffness to a point which likely outweighs benefits, and risks increased complications. …”
  9. 2329

    Data Sheet 1_Characterizing the structural properties and porosity of mid-urethral slings with varied manufacturing techniques.docx by Katrina Knight (17391604)

    Published 2025
    “…</p>Discussion<p>Overall, heat-sealing decreased deformability at the cost of markedly increasing device stiffness to a point which likely outweighs benefits, and risks increased complications. …”
  10. 2330

    DataSheet1_Effects of Qingjin Huatan decoction on pulmonary function and inflammatory mediators in acute exacerbations of chronic obstructive pulmonary disease: a systematic review... by Xuqin Du (8803772)

    Published 2024
    “…Compared to conventional treatment, QHD significantly improved pulmonary function, with increases in FEV1 (MD = 0.30, 95% CI: 0.26 to 0.34, p = 0.000), FVC (MD = 0.34, 95% CI: 0.27 to 0.41, p = 0.000), FEV1/FVC (MD = 6.07, 95% CI: 5.55 to 6.58, p = 0.000), and PaO<sub>2</sub> (MD = 7.20, 95% CI: 4.94 to 9.47, p = 0.000), and a decrease in PaCO<sub>2</sub> (MD = −5.37, 95% CI: 7.99 to −2.74, p = 0.000). …”
  11. 2331

    DataSheet2_Effects of Qingjin Huatan decoction on pulmonary function and inflammatory mediators in acute exacerbations of chronic obstructive pulmonary disease: a systematic review... by Xuqin Du (8803772)

    Published 2024
    “…Compared to conventional treatment, QHD significantly improved pulmonary function, with increases in FEV1 (MD = 0.30, 95% CI: 0.26 to 0.34, p = 0.000), FVC (MD = 0.34, 95% CI: 0.27 to 0.41, p = 0.000), FEV1/FVC (MD = 6.07, 95% CI: 5.55 to 6.58, p = 0.000), and PaO<sub>2</sub> (MD = 7.20, 95% CI: 4.94 to 9.47, p = 0.000), and a decrease in PaCO<sub>2</sub> (MD = −5.37, 95% CI: 7.99 to −2.74, p = 0.000). …”
  12. 2332

    Table1_Effects of Qingjin Huatan decoction on pulmonary function and inflammatory mediators in acute exacerbations of chronic obstructive pulmonary disease: a systematic review and... by Xuqin Du (8803772)

    Published 2024
    “…Compared to conventional treatment, QHD significantly improved pulmonary function, with increases in FEV1 (MD = 0.30, 95% CI: 0.26 to 0.34, p = 0.000), FVC (MD = 0.34, 95% CI: 0.27 to 0.41, p = 0.000), FEV1/FVC (MD = 6.07, 95% CI: 5.55 to 6.58, p = 0.000), and PaO<sub>2</sub> (MD = 7.20, 95% CI: 4.94 to 9.47, p = 0.000), and a decrease in PaCO<sub>2</sub> (MD = −5.37, 95% CI: 7.99 to −2.74, p = 0.000). …”
  13. 2333
  14. 2334
  15. 2335
  16. 2336
  17. 2337
  18. 2338
  19. 2339
  20. 2340